# Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

> **NCT06118099** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 90 (actual)

## Conditions studied

- Hidradenitis

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06118099
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-01
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-10-10
- **Target enrollment:** 90 (ACTUAL)
- **Why stopped:** Sponsor decision; the decision is not related to any safety concern
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06118099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06118099, "Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06118099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*